Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ophthalmic drug discovery.

Abbot F Clark1, Thomas Yorio

  • 1Alcon Research, Ltd, Fort Worth, Texas 76134, USA. abe.clark@alconlabs.com

Nature Reviews. Drug Discovery
|May 31, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacological restoration of impaired autophagy in retinal ganglion cells prevents abnormal mitochondrial accumulation and glaucomatous neurodegeneration.

Molecular neurodegeneration·2026
Same author

Mechanistic Insights into Glucocorticoid-Induced Ocular Hypertension Using Differences in Mouse Strain Responsiveness.

The American journal of pathology·2025
Same author

Therapeutic mRNA delivery of CRISPR-Cas9 to the trabecular meshwork reverses ocular hypertension in myocilin glaucoma.

Molecular therapy. Methods & clinical development·2025
Same author

Biodistribution of Reconstituted High-Density Lipoprotein Nanoparticles for Targeted Delivery to Retinal Ganglion Cells.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics·2025
Same author

C/EBP Homologous Protein Expression in Retinal Ganglion Cells Induces Neurodegeneration in Mice.

International journal of molecular sciences·2025
Same author

Phenethylaminylation: Preliminary <i>In Vitro</i> Evidence for the Covalent Transamidation of Psychedelic Phenethylamines to Glial Proteins using 3,5-Dimethoxy-4-(2-Propynyloxy)-Phenethylamine as a Model Compound.

bioRxiv : the preprint server for biology·2025

New therapies are needed for age-related macular degeneration and glaucoma, leading causes of blindness. This review explores novel approaches to halt or reverse these challenging ocular diseases.

Area of Science:

  • Ophthalmology
  • Drug Discovery
  • Cellular Biology

Background:

  • Millions suffer from ocular diseases, many leading to irreversible blindness.
  • Age-related macular degeneration and glaucoma are leading causes of blindness in the elderly, with increasing prevalence.
  • Current treatments for glaucoma exist, and age-related macular degeneration treatments are in clinical trials, yet more effective therapies are needed.

Purpose of the Study:

  • To provide insight into new therapeutic approaches for ocular diseases.
  • To highlight the challenges and opportunities in ocular drug discovery.
  • To discuss emerging drug targets based on cellular mechanisms of disease.

Main Methods:

  • Review of current literature on ocular diseases and therapeutic strategies.

Related Experiment Videos

  • Analysis of cellular mechanisms underlying age-related macular degeneration and glaucoma.
  • Exploration of novel drug delivery and discovery approaches for the eye.

    • Main Results:

    • Identified a significant need for more efficacious treatments for age-related macular degeneration and glaucoma.
    • Highlighted the complexity of the eye as an organ for drug discovery.
    • Indicated that understanding cellular mechanisms can lead to new drug targets.

    Conclusions:

    • Further research into cellular mechanisms is crucial for developing novel therapies.
    • The eye's unique properties present both challenges and advantages for local drug delivery.
    • Emerging therapeutic strategies hold promise for halting or reversing vision loss from ocular diseases.